-
Suzhou GenAssist Launches First-of-Its-Kind Base Editing Drug Trial for Duchenne Muscular Dystrophy
•
Suzhou GenAssist Therapeutic Co., Ltd, a biopharmaceutical company based in China, has announced the commencement of an investigator-initiated-trial (ITT) for its base editing drug candidate, GEN6050X, in patients afflicted with Duchenne muscular dystrophy (DMD). DMD is a rare genetic disorder linked to the X-chromosome, typically caused by mutations in the…
-
Siemens Healthineers’ 7T MRI System Terra. X Receives NMPA Marketing Approval
•
Siemens Healthineers AG has secured marketing approval from China’s National Medical Products Administration (NMPA) for its Magnetom Terra X, a localized next-generation 7T magnetic resonance imaging (MRI) system. This marks a significant advancement in medical imaging technology within the Chinese market. Terra. X, the first domestically produced 7T clinical MRI…
-
Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting
•
Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings from the Phase III DREAMS-2 study on its drug candidate mazdutide at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD). Mazdutide, a dual agonist targeting the glucagon-like peptide-1 receptor…
-
CSA Medical Inc. Secures USD 53 Million in Series D Financing to Advance Cryotherapy Treatment
•
CSA Medical Inc., a U.S.-based medical technology company, has successfully closed a Series D financing round, securing USD 53 million in capital. This financing was co-led by TVM Capital Life Science and China-focused Yonjin Ventures, with significant participation from existing investors including SV Health Investors, Ascension Ventures, First Analysis, Blue…
-
Celltrion Inc. Enters CDMO Arena Amid Shifts in Global Biosecurity Landscape
•
South Korea’s biosimilars giant, Celltrion Inc., is gearing up to expand into the contract development and manufacturing organization (CDMO) sector, according to a company presentation this week. The announcement follows Celltrion’s founder and Chairman Seo Jung-jin’s remarks at the Morgan Stanley 22nd Annual Global Healthcare Conference last week. Seo revealed…
-
Gilead Sciences Partners with AI Firm Genesis Therapeutics to Develop Novel Small-Molecule Therapies
•
Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company based in the U.S., has entered into a strategic collaboration with Genesis Therapeutics Inc., an AI-driven drug development firm, to discover and develop innovative small-molecule therapies across a range of therapeutic targets. Under the terms of the agreement, Genesis will receive an…
-
Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies
•
Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage therapies, has announced an expansion of its collaboration with fellow U.S. firm Moderna Inc. (NASDAQ: MRNA). This strategic partnership extension will focus on the development of in vivo CAR macrophage and monocyte (CAR-M) therapies for…
-
Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector
•
Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with two domestic biotechnology companies: Lakeshore Biotechnology, a cell and gene therapy (CGT) focused biotech, and Porton Pharma Solutions, Ltd., a CGT contract research organization (CRO) and contract development and manufacturing organization (CDMO). In July, Itcure…
